Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18
根据 EGFR 和 ALK 状态评估，在不可切除的局部晚期 III 期非小细胞肺癌患者接受根治性同步放化疗后，Durvalumab 维持治疗的临床结果：韩国癌症研究组 LU-22-18
期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2024.100734
Choi, Dae-Ho; Kim, Miso; Kim, Young Saing; Park, Keon Uk; Cho, Jang Ho; Kim, Hongsik; Lee, Ki Hyeong; Ahn, Heejoon; Kim, Il-Hwan; Lee, Kyung-Hee; Lee, Gyeong-Won; Yi, Seong Yoon; Ahn, Beung Chul; Lee, Min-Young; Jung, Hyun Ae; Park, Sehhoon; Sun, Jong-Mu; Ahn, Jin Seok; Lee, Se-Hoon; Ahn, Myung-Ju
